CMS assigns reimbursement code for EyePoint implant 3 months early

A permanent reimbursement code for YUTIQ, an implant intended to treat chronic eye inflammation made by EyePoint Pharmaceuticals, was assigned by CMS one quarter early.

Advertisement

Three details:

1. The code, J7314, will become effective Oct. 1 , earlier than the usually scheduled time at the beginning of the upcoming year.

2. In the past, CMS issued J-codes for reimbursement yearly, but now releases them quarterly.

3. “YUTIQ reimbursement is currently being processed through the utilization of either a miscellaneous or a shared billing code, and payer support for reimbursement of YUTIQ has been positive. The Oct. 1 effective date of a permanent J-code specific to YUTIQ will allow treating physicians, insurers and patients to benefit sooner from a more streamlined approval and reimbursement process,” said Nancy Lurker, president and CEO of EyePoint Pharmaceuticals.

More articles on supply chain:
ASC supply chain tip of the day: Compile procedure packs
ASC supply chain tip: Track expenses
Strategic Radiology enters into vendor agreement with Samsung affiliate — 3 insights

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply chain

Advertisement

Comments are closed.